文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

Quality of life status determinants in hypertrophic cardiomyopathy as evaluated by the Kansas City Cardiomyopathy Questionnaire.

作者信息

Capota Razvan, Militaru Sebastian, Ionescu Alin Alexandru, Rosca Monica, Baicus Cristian, Popescu Bogdan Alexandru, Jurcut Ruxandra

机构信息

Expert Center for Rare Genetic Cardiovascular Diseases, Emergency Institute for Cardiovascular Diseases "Prof.Dr.C.C.Iliescu", Sos. Fundeni 258, 022322, Bucharest, Romania.

University of Medicine and Pharmacy "Carol Davila", Bucharest, Romania.

出版信息

Health Qual Life Outcomes. 2020 Oct 30;18(1):351. doi: 10.1186/s12955-020-01604-9.


DOI:10.1186/s12955-020-01604-9
PMID:33126893
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7602300/
Abstract

PURPOSE: The present study evaluated how heart failure (HF) negatively impacts health-related quality of life (HRQoL) in hypertrophic cardiomyopathy (HCM) patients and explored the major clinical determinants associated with HRQoL impairment in this population. METHODS: This was a cross-sectional single-center study of health-related HRQoL that included 91 consecutive patients with HCM. Evaluation was performed based on a comprehensive protocol that included the recommended diagnostic studies, as well as administration of the translated validated version of the Kansas City Cardiomyopathy Questionnaire (KCCQ) (CV Outcomes Inc) as a health status measure. RESULTS: The cohort included 52 (57%) males, median age 58 (20-85) years. The median global KCCQ score was 67 (12.5-100) corresponding to a moderate impairment in HRQoL. There was an inverse correlation between the median global KCCQ score and NYHA class (Kendall's tau b coefficient r - 0.33, p = 0.001). Patients with pulmonary hypertension (PHT), defined as resting pulmonary artery systolic pressure of ≥ 45 mmHg, presented a significantly worse HRQoL as compared to those without PHT (median KCCQ score 56.2 vs 77.5, p = 0.013). The KCCQ score mildly correlated with age (r - 0.18, p = 0.014), history of syncope (r - 0.18, p = 0.045), estimated glomerular filtration rate (eGFR) (r 0.31, p < 0.001), plasmatic creatinine (r - 0.18, p = 0.017) and urea levels (r - 0.27, p < 0.001), left ventricular (LV) end-systolic dimensions (r - 0.18, p = 0.014), maximal provoked intraventricular gradient (r 0.20, p = 0.039), LV ejection fraction (r 0.15, p = 0.04), average E/e' (r - 0.16, p = 0.039), pulmonary acceleration time (r 0.21, p = 0.007), pulmonary artery systolic pressure (r - 0.20, p = 0.016). In ordinal regression, the independent predictors of HRQoL were NYHA class and eGFR. CONCLUSIONS: Patients with HCM and HF present a moderate degree of alteration in HRQoL. This is especially true for patients with PHT and more severe functional impairment. Renal failure and NYHA class are potential markers of HRQoL in clinical practice.

摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ecce/7602300/f4533d268667/12955_2020_1604_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ecce/7602300/f4533d268667/12955_2020_1604_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ecce/7602300/f4533d268667/12955_2020_1604_Fig1_HTML.jpg

相似文献

[1]
Quality of life status determinants in hypertrophic cardiomyopathy as evaluated by the Kansas City Cardiomyopathy Questionnaire.

Health Qual Life Outcomes. 2020-10-30

[2]
Correlations between physician-perceived functional status, patient-perceived health status, and cardiopulmonary exercise results in hypertrophic cardiomyopathy.

Qual Life Res. 2012-4-29

[3]
Comparison Between the Kansas City Cardiomyopathy Questionnaire and New York Heart Association in Assessing Functional Capacity and Clinical Outcomes.

J Card Fail. 2017-4

[4]
Validation of heart failure quality of life tool and usage to predict all-cause mortality in acute heart failure in Uganda: the Mbarara heart failure registry (MAHFER).

BMC Cardiovasc Disord. 2018-12-12

[5]
New York Heart Association Class and Kansas City Cardiomyopathy Questionnaire in Acute Heart Failure.

JAMA Netw Open. 2023-10-2

[6]
Psychometric properties of the Japanese version of the Kansas City Cardiomyopathy Questionnaire in Japanese patients with chronic heart failure.

Health Qual Life Outcomes. 2020-7-17

[7]
Comparing Measures to Assess Health-Related Quality of Life in Heart Failure With Preserved Ejection Fraction.

JACC Heart Fail. 2018-6-6

[8]
Testosterone and quality of life in patients with dilated cardiomyopathy.

Discoveries (Craiova). 2022-9-29

[9]
Adapting and usability testing of the Kansas city cardiomyopathy questionnaire (KCCQ) in a heart failure clinic in Tanzania: the Swahili KCCQ.

BMC Cardiovasc Disord. 2023-5-6

[10]
Validation of the Kansas City Cardiomyopathy Questionnaire in Symptomatic Obstructive Hypertrophic Cardiomyopathy.

JACC Heart Fail. 2022-8

引用本文的文献

[1]
Efficacy of cardiac myosin inhibitors mavacamten and aficamten in hypertrophic cardiomyopathy: a systematic review and meta-analysis of randomised controlled trials.

Open Heart. 2025-2-23

[2]
Treatment patterns, outcomes and healthcare resource utilization of obstructive hypertrophic cardiomyopathy in England.

ESC Heart Fail. 2025-6

[3]
Obstructive hypertrophic cardiomyopathy: from genetic insights to a multimodal therapeutic approach with mavacamten, aficamten, and beyond.

Egypt Heart J. 2024-12-7

[4]
Loss of quality of life and increased societal costs in patients with hypertrophic cardiomyopathy: the AFFECT-HCM study.

Eur Heart J Qual Care Clin Outcomes. 2025-3-3

[5]
Quality of Life and Exercise Capacity in Early Stage and Subclinical Hypertrophic Cardiomyopathy: A Secondary Analysis of the VANISH Trial.

Circ Heart Fail. 2024-8

[6]
Exploring Health-Related Quality of Life in Children With Hypertrophic Cardiomyopathy and Relationship to Physical Activity.

J Am Heart Assoc. 2024-6-18

[7]
Evaluating the efficacy and safety of mavacamten in hypertrophic cardiomyopathy: A systematic review and meta-analysis focusing on qualitative assessment, biomarkers, and cardiac imaging.

PLoS One. 2024

[8]
Are disease-specific patient-reported outcomes measures (PROMs) used in cardiogenetics? A systematic review.

Eur J Hum Genet. 2024-6

[9]
Short-term study of atrial shunt and improvement of functional mitral regurgitation.

J Cardiothorac Surg. 2023-11-15

[10]
Assessment of left ventricular global longitudinal strain in patients with hypertrophic cardiomyopathy and coronary artery disease.

Int J Cardiovasc Imaging. 2024-2

本文引用的文献

[1]
Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial.

Lancet. 2020-8-29

[2]
Study Design and Rationale of EXPLORER-HCM: Evaluation of Mavacamten in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy.

Circ Heart Fail. 2020-6-5

[3]
International Consortium for Health Outcomes Measurement (ICHOM): Standardized Patient-Centered Outcomes Measurement Set for Heart Failure Patients.

JACC Heart Fail. 2020-3

[4]
Clinical Course and Quality of Life in High-Risk Patients With Hypertrophic Cardiomyopathy and Implantable Cardioverter-Defibrillators.

Circ Arrhythm Electrophysiol. 2018-4

[5]
Standardization of adult transthoracic echocardiography reporting in agreement with recent chamber quantification, diastolic function, and heart valve disease recommendations: an expert consensus document of the European Association of Cardiovascular Imaging.

Eur Heart J Cardiovasc Imaging. 2017-12-1

[6]
Comparison Between the Kansas City Cardiomyopathy Questionnaire and New York Heart Association in Assessing Functional Capacity and Clinical Outcomes.

J Card Fail. 2017-4

[7]
Hypertrophic obstructive cardiomyopathy.

Lancet. 2016-11-30

[8]
Health-related quality of life in hypertrophic cardiomyopathy patients with implantable defibrillators.

Health Qual Life Outcomes. 2016-4-14

[9]
2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC).

Eur Heart J. 2014-10-14

[10]
Quantitative Doppler-echocardiographic imaging and clinical outcomes with left ventricular systolic dysfunction: independent effect of pulmonary hypertension.

Circ Cardiovasc Imaging. 2014-1-31

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索